QLT names CEO
QLT acting CEO Robert Butchofsky will fill the top post permanently. After an extensive search, the board decided to appoint Butchofsky based on his performance as acting chief since September 2005. Butchofsky joined QLT in 1998 and is credited with launching and commercializing the company's lead drug, the age-related macular degeneration injection Visudyne (vertaporfin). He previously worked for Allergan...
You may also be interested in...
CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.
The US FDA appears to have concerns about the device used to administer the vaccine.
The US Medicare agency has released a quick-start guide for laboratory certification.